ASH 2018 | Significantly improving HRQL and neurocognition in high-risk sickle cell following familial ASCT
Mitchell Cairo, MD, of New York Medical College, Valhalla, NY, discusses the NYMC-571 trial (NCT02675959). This showed significantly improved long-term health-related quality of life and neurocognition in high-risk sickle cell disease patients following familial haploidentical stem cell transplantation that used CD34-enriched and CD3 mononuclear addback. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up